Strides gets USFDA nod for generic Oxybutynin Chloride tablets
Company's step-down wholly owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food& Drug Administration (USFDA), Strides said in a filing to BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 18, 2020 Category: Pharmaceuticals Source Type: news

Incontinence Drug May Help Ease Severe Hot Flashes
Oxybutynin, a drug widely used to treat urinary incontinence caused by an overactive bladder, helps treat hot flashes in breast cancer survivors and women who did not have breast cancer but who were bothered by frequent or severe menopausal symptoms, new research shows. (Source: WebMD Health)
Source: WebMD Health - December 17, 2018 Category: Consumer Health News Source Type: news

' It's Going to Be a Useful Agent': Oxybutynin for Hot Flashes'It's Going to Be a Useful Agent': Oxybutynin for Hot Flashes
A urinary incontinence drug is surprisingly effective in the treatment of hot flashes for both women with a history of breast cancer and those with menopausal symptoms but who do not have cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oxybutynin can reduce hot flashes in breast cancer survivors
Research, presented at the San Antonio Breast Cancer Symposium, suggests that the drug oxybutynin can reduce the severity of hot flashes in patients who have had breast cancer. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 10, 2018 Category: Endocrinology Source Type: news

Oxybutynin Helps Curb Hot Flashes in Breast Ca Patients
(MedPage Today) -- Women report better hot flash interference scores, quality of life (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 9, 2018 Category: Endocrinology Source Type: news

Incontinence Drug, Oxybutynin (Ditropan XL) May Cut Hot Flashes in Breast Cancer Survivors
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2018 Category: General Medicine Source Type: news

Incontinence Drug Oxybutynin May Cut Hot Flashes in Breast Cancer Survivors
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2018 Category: General Medicine Source Type: news

Incontinence Drug May Cut Hot Flashes in Breast Cancer Survivors
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2018 Category: General Medicine Source Type: news

Mayo-led study: Drug reduces hot flashes, improves breast cancer survivor quality of life
(Mayo Clinic) Research led by oncologists Roberto Leon-Ferre, M.D. and Charles Loprinzi, M.D. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors. These findings were presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2018 Category: International Medicine & Public Health Source Type: news

Oxybutynin decreased frequency of hot flashes, improved QOL for breast cancer survivors
(American Association for Cancer Research) Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2018 Category: Cancer & Oncology Source Type: news

Oxybutynin lessens hot flash frequency, improves breast cancer survivor quality of life, Mayo-led study finds
SAN ANTONIO ? Research led by oncologists Roberto Leon-Ferre, M.D. and Charles Loprinzi, M.D. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors. These findings were presented at the 2018 San [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - December 7, 2018 Category: Research Source Type: news

Ditropan (Oxybutynin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 8, 2018 Category: Drugs & Pharmacology Source Type: news

Oxytrol (Oxybutynin Transdermal) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 2, 2017 Category: Drugs & Pharmacology Source Type: news

Oxybutynin Frequently Prescribed in OAB (CME/CE)
(MedPage Today) -- Antimuscarinic with cognitive side effects often given to older patients with bladder symptoms (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - May 15, 2017 Category: OBGYN Source Type: news

Oxybutynin Use'Alarmingly High' in Older Patients Oxybutynin Use'Alarmingly High' in Older Patients
Despite well-documented links between antimuscarinic agents and dementia in the elderly, inappropriate prescribing continues, and might be driven by restrictive formularies and a lack of awareness.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2017 Category: Consumer Health News Tags: Urology News Source Type: news